Cancer immunotherapy .net

Cattle Ocular squamous cell carcinoma

1989

cancerimmunotherapy@yahoo.com

tumour type

Rutten VP, Klein WR, De Jong WA, Misdorp W, Den Otter W, Steerenberg PA, De Jong WH, Ruitenberg EJ. Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol. Immunother. (1989) 30, 165 Five cows bearing bovine ocular squamous cell carcinoma (BOSCC) were treated with low doses of recombinant human interleukin-2 (rhIL-2). A dose of 2500 U rhIL-2 was injected intralesionally and another 2500 U were injected into the subparotid regional lymph node once a day during a period of 5 consecutive days. This cycle of 5 days was repeated after an interval of 2 days. Total regression of the tumor was observed in three out of five animals. One cow showed tumor regression (greater than 80%) accompanied by metastases to the regional lymph node that were observed from the fifth week after the beginning of the treatment. Growth of the tumor of the fifth animal was retarded after treatment. In vitro proliferation of peripheral blood lymphocytes was investigated in two animals and tumor-infiltrating lymphocytes in one animal during incubation in various rhIL-2 concentrations. Cytotoxic activity of both cell populations against P815, Yac-1 and BOSCC-derived cell lines increased during incubation with rhIL-2. Cultured BOSCC-infiltrating lymphocytes showed predominant killing of the BOSCC-derived autologous cell line after 4 weeks of culture. Preliminary phenotype analysis did not give conclusive results with respect to the types of cells responsible for killing. Publication Types: Clinical Trial, Phase I, Phase II

1993

Den Otter W, Hill FW, Klein WR, Koten JW, Steerenberg PA, De Mulder PH, Rutten VP, Ruitenberg EJ. Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res. (1993) 13, 2453 Four cows bearing large Ocular Squamous Cell Carcinomas (BOSCC) were treated by 10 intratumoral injections (Monday-Friday for 2 consecutive weeks) of 200,000 U Interleukin-2 (Cetus). Tumors regressed in 2 out of 4 cases. This result shows that even large tumors may regress after local IL-2 treatment. Publication Types: Clinical Trial, Phase I, Phase II

1995

Den Otter W, Hill FW, Klein WR, Koten JW, Steerenberg PA, De Mulder PH, Rhode C, Stewart R, Faber JA, Ruitenberg EJ, et al Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother. (1995) 41, 10 We have tested the therapeutic potency of peritumorally injected low doses of interleukin-2 (IL-2). Seventy tumours of the bovine ocular squamous-cell carcinoma (BOSCC), 1-3 cm in diameter, were treated with 5000, 20,000 or 200,000 U IL-2 from Eurocetus (Chiron) to find the optimal dose for treatment. Injections were given peritumorally on Monday to Friday on 2 consecutive weeks. The size of the tumours was measured before treatment and 1, 3, 4, 9 and 20 months after treatment. After 9 months complete regression was observed in 89% of the tumours treated with 5000 U IL-2, 80% treated with 20,000 U and 67% treated with 200,000 U. After 20 months, there was complete regression of 35%, 31% and 67% of the tumours respectively. The 9- and 20-month results of the 200,000-U treatment are significantly better than those of the 5000-U and 20,000-U treatments taken together. This protocol may be useful to treat advanced inoperable tumours (e.g. of the nasopharynx or skin) of human patients. Publication Types: Clinical Trial, Phase I, Phase II

2004

Stewart RJE, Hill FWG, Masztalerz A, Jacobs JJL, Koten JW, Den Otter W Peritumoural low dose Interleukin-2 therapy of bovine ocular squamous cell carcinomas: An effective therapy. Vet. Record (in press) ... Publication Types: Clinical Trial, Phase I, Phase II

Stewart RJE, Masztalerz A, Jacobs JJL, Den Otter W Local Interleukin-2 and Interleukin-12 therapy fof bovine ocular squamous cell carcinomas. Vet. Immunol. Immunopath. (in press) ... Publication Types: Clinical Trial, Phase I, Phase II

tumour type

Interleukin-2 (IL-2) Mechanism of IL-2 therapy of cancer Cancers sensitve to IL-2 Surgery and IL-2 Radiotherapy and IL-2 Chemotherapy and IL-2 Experts I want to co-operate (doctors) Frequently Asked Questions (FAQs)

Information for doctors Information for patients I want to support this research or  more information on the EPTI fund supporting this research

Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands